Human serum albumin (HSA) has been identified as a powerful tool for the expansion of many cell types in vitro . HSA is a multifaceted protein capable of binding many different types of molecules . HSA therefore plays diverse roles in cell biology, acting as an antioxidant to improve health of cells by binding to reactive oxygen species, as an energy-delivery system by chaperoning fatty acids in the bloodstream, and as a mediator for solubilization and stabilization of metal ions required for cellular processes [2,3]. These functions make HSA supplementation of cell culture media an integral step in facilitating cell growth and expansion in vitro, especially when removing serum or blood-derived proteins for use in clinical manufacturing. Using Cellastim S as a recombinant and scalable source of albumin in cell culture is an enabling tool for large-scale manufacture of cell-based and gene therapies. It is the goal of this app note to provide a step-by-step overview for preparing Cellastim S for use as a stock liquid solution for in vitro cell culture applications.
Posted By Marcus Curl on 6/18/19 8:53 AM
Recently I had the opportunity to attend the Treg Summit in Boston to listen to the ground-breaking clinical and preclinical research in re-balancing the immune system in the context of autoimmunity and organ transplant via the use of polyclonal or antigen-induced T regulatory cells. Overall, this cell therapy holds immense promise as evidenced by both preclinical models and early clinical evaluations.
Cellastim S Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells
Posted By Jeanne McAdara Ph.D. on 5/9/19 11:00 AM
The number and breadth of applications for induced human embryonic and pluripotent stem cells (hi-ESCs and hi-PSCs) in both research and clinical settings continue to co-evolve with our understanding of how to harness them as biological tools.
Last week InVitria attended and celebrated the 25th anniversary of the Biotechnology Industry Organization (BIO) at their annual conference. More than 18,000 delegates over 7,000 companies flew in from around the world and joined InVitria at this event in Boston. A few highlights that emerged from the BIO 2018 conference include: